VEGFA and colorectal cancer: Antiangiogenic agents, including small molecule inhibitors and monoclonal antibodies (mAbs) targeting VEGF (e.g., bevacizumab) or VEGFR2 (e.g., ramucirumab), are US Food and Drug Administration (FDA) approved for the treatment of renal cell carcinoma, colorectal cancer, gastric cancer, non-small-cell lung cancer, and a number of other indications (4).